The association between p53 expression, stage and histological features in endometrial cancer

Nicola Ragni, Simone Ferrero, Federico Prefumo, Barbara Muschiato, Franco Gorlero, Marina Gualco, Ezio Fulcheri

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: Alterations of the p53 gene have been widely suggested to be relevant to the development of endometrial carcinoma. However, contradictory results have been reported when immunohistochemical determination of p53 expression has been correlated with stage and histological features of the tumours. Study design: Pathology findings were reviewed and p53 immunoperoxidase staining was performed in 240 cases of endometrial carcinoma. Results: Uterine papillary serous adenocarcinomas showed significantly higher p53 overexpression than uterine endometrioid adenocarcinomas (100.0% versus 61.0%, p <0.005). p53 overexpression was significantly higher in the secretory variant (85.7%) than in the typical endometrioid carcinoma (60.0%) (p <0.05). p53 expression did not differ between early (stage I) and advanced (stage II-IV) carcinomas. Likewise, no difference was observed in p53 expression among different architectural grades. The incidence of metastasis to lymph nodes was similar in p53 positive (13.7%) and in p53 negative tumours (12.5%). Conclusion: In the present series, p53 immunostaining did not differ between cases with different FIGO stages or histologic characteristics of the tumours. No simple relationship exists between the immunohistochemical determination of p53 expression and the biological aggressiveness of endometrial carcinomas.

Original languageEnglish
Pages (from-to)111-116
Number of pages6
JournalEuropean Journal of Obstetrics and Gynecology and Reproductive Biology
Volume123
Issue number1
DOIs
Publication statusPublished - Nov 1 2005

Fingerprint

Endometrial Neoplasms
Endometrioid Carcinoma
Papillary Adenocarcinoma
Neoplasms
p53 Genes
Lymph Nodes
Pathology
Staining and Labeling
Neoplasm Metastasis
Carcinoma
Incidence

Keywords

  • Endometrial carcinoma
  • Grade
  • Immunohistochemistry
  • p53
  • Stage

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

The association between p53 expression, stage and histological features in endometrial cancer. / Ragni, Nicola; Ferrero, Simone; Prefumo, Federico; Muschiato, Barbara; Gorlero, Franco; Gualco, Marina; Fulcheri, Ezio.

In: European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 123, No. 1, 01.11.2005, p. 111-116.

Research output: Contribution to journalArticle

Ragni, Nicola ; Ferrero, Simone ; Prefumo, Federico ; Muschiato, Barbara ; Gorlero, Franco ; Gualco, Marina ; Fulcheri, Ezio. / The association between p53 expression, stage and histological features in endometrial cancer. In: European Journal of Obstetrics and Gynecology and Reproductive Biology. 2005 ; Vol. 123, No. 1. pp. 111-116.
@article{f7b5ce2b99ce4785b92c0398237787ae,
title = "The association between p53 expression, stage and histological features in endometrial cancer",
abstract = "Objective: Alterations of the p53 gene have been widely suggested to be relevant to the development of endometrial carcinoma. However, contradictory results have been reported when immunohistochemical determination of p53 expression has been correlated with stage and histological features of the tumours. Study design: Pathology findings were reviewed and p53 immunoperoxidase staining was performed in 240 cases of endometrial carcinoma. Results: Uterine papillary serous adenocarcinomas showed significantly higher p53 overexpression than uterine endometrioid adenocarcinomas (100.0{\%} versus 61.0{\%}, p <0.005). p53 overexpression was significantly higher in the secretory variant (85.7{\%}) than in the typical endometrioid carcinoma (60.0{\%}) (p <0.05). p53 expression did not differ between early (stage I) and advanced (stage II-IV) carcinomas. Likewise, no difference was observed in p53 expression among different architectural grades. The incidence of metastasis to lymph nodes was similar in p53 positive (13.7{\%}) and in p53 negative tumours (12.5{\%}). Conclusion: In the present series, p53 immunostaining did not differ between cases with different FIGO stages or histologic characteristics of the tumours. No simple relationship exists between the immunohistochemical determination of p53 expression and the biological aggressiveness of endometrial carcinomas.",
keywords = "Endometrial carcinoma, Grade, Immunohistochemistry, p53, Stage",
author = "Nicola Ragni and Simone Ferrero and Federico Prefumo and Barbara Muschiato and Franco Gorlero and Marina Gualco and Ezio Fulcheri",
year = "2005",
month = "11",
day = "1",
doi = "10.1016/j.ejogrb.2005.03.018",
language = "English",
volume = "123",
pages = "111--116",
journal = "European Journal of Obstetrics, Gynecology and Reproductive Biology",
issn = "0028-2243",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - The association between p53 expression, stage and histological features in endometrial cancer

AU - Ragni, Nicola

AU - Ferrero, Simone

AU - Prefumo, Federico

AU - Muschiato, Barbara

AU - Gorlero, Franco

AU - Gualco, Marina

AU - Fulcheri, Ezio

PY - 2005/11/1

Y1 - 2005/11/1

N2 - Objective: Alterations of the p53 gene have been widely suggested to be relevant to the development of endometrial carcinoma. However, contradictory results have been reported when immunohistochemical determination of p53 expression has been correlated with stage and histological features of the tumours. Study design: Pathology findings were reviewed and p53 immunoperoxidase staining was performed in 240 cases of endometrial carcinoma. Results: Uterine papillary serous adenocarcinomas showed significantly higher p53 overexpression than uterine endometrioid adenocarcinomas (100.0% versus 61.0%, p <0.005). p53 overexpression was significantly higher in the secretory variant (85.7%) than in the typical endometrioid carcinoma (60.0%) (p <0.05). p53 expression did not differ between early (stage I) and advanced (stage II-IV) carcinomas. Likewise, no difference was observed in p53 expression among different architectural grades. The incidence of metastasis to lymph nodes was similar in p53 positive (13.7%) and in p53 negative tumours (12.5%). Conclusion: In the present series, p53 immunostaining did not differ between cases with different FIGO stages or histologic characteristics of the tumours. No simple relationship exists between the immunohistochemical determination of p53 expression and the biological aggressiveness of endometrial carcinomas.

AB - Objective: Alterations of the p53 gene have been widely suggested to be relevant to the development of endometrial carcinoma. However, contradictory results have been reported when immunohistochemical determination of p53 expression has been correlated with stage and histological features of the tumours. Study design: Pathology findings were reviewed and p53 immunoperoxidase staining was performed in 240 cases of endometrial carcinoma. Results: Uterine papillary serous adenocarcinomas showed significantly higher p53 overexpression than uterine endometrioid adenocarcinomas (100.0% versus 61.0%, p <0.005). p53 overexpression was significantly higher in the secretory variant (85.7%) than in the typical endometrioid carcinoma (60.0%) (p <0.05). p53 expression did not differ between early (stage I) and advanced (stage II-IV) carcinomas. Likewise, no difference was observed in p53 expression among different architectural grades. The incidence of metastasis to lymph nodes was similar in p53 positive (13.7%) and in p53 negative tumours (12.5%). Conclusion: In the present series, p53 immunostaining did not differ between cases with different FIGO stages or histologic characteristics of the tumours. No simple relationship exists between the immunohistochemical determination of p53 expression and the biological aggressiveness of endometrial carcinomas.

KW - Endometrial carcinoma

KW - Grade

KW - Immunohistochemistry

KW - p53

KW - Stage

UR - http://www.scopus.com/inward/record.url?scp=27644446130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644446130&partnerID=8YFLogxK

U2 - 10.1016/j.ejogrb.2005.03.018

DO - 10.1016/j.ejogrb.2005.03.018

M3 - Article

VL - 123

SP - 111

EP - 116

JO - European Journal of Obstetrics, Gynecology and Reproductive Biology

JF - European Journal of Obstetrics, Gynecology and Reproductive Biology

SN - 0028-2243

IS - 1

ER -